Basic Concepts in Population Modeling, Simulation, and Model-based Drug Development-part 2: Introduction to Pharmacokinetic Modeling Methods

Overview

Journal CPT Pharmacometrics Syst Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2013 Jul 27

PMID 23887688

Citations 331

Authors

D R Mould

R N Upton

Affiliations

Soon will be listed here.

Citing Articles

Population Pharmacokinetics of IV Lidocaine and its Metabolites in Adult Surgical Patients.

Foong K, Loh P, Chaw S, Lo Y Pharm Res. 2025; .

PMID: 40021547 DOI: 10.1007/s11095-025-03835-1.

Editorial on Special Issue "Pharmacokinetics, Pharmacodynamics, and Drug Interactions".

Zhou Z Pharmaceutics. 2025; 17(2).

PMID: 40006632 PMC: 11859146. DOI: 10.3390/pharmaceutics17020266.

Multidose Dalbavancin Population Pharmacokinetic Analysis for Prolonged Target Attainment in Patients Requiring Long-Term Treatment.

Baiardi G, Cameran Caviglia M, Boni S, Di Paolo A, Marini V, Cangemi G Antibiotics (Basel). 2025; 14(2).

PMID: 40001433 PMC: 11852064. DOI: 10.3390/antibiotics14020190.

The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models.

Nyberg J, Jonsson E J Pharmacokinet Pharmacodyn. 2025; 52(2):18.

PMID: 39985638 PMC: 11846770. DOI: 10.1007/s10928-025-09964-9.

Defining preclinical efficacy with the DNAPK inhibitor AZD7648 in combination with olaparib: a minimal systems pharmacokinetic-pharmacodynamic model.

DeJongh J, Cadogan E, Davies M, Ramos-Montoya A, Smith A, van Steeg T J Pharmacokinet Pharmacodyn. 2025; 52(2):17.

PMID: 39961902 PMC: 11832700. DOI: 10.1007/s10928-025-09962-x.

References

Tunblad K, Lindbom L, McFadyen L, Jonsson E, Marshall S, Karlsson M . The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data. J Pharmacokinet Pharmacodyn. 2008; 35(5):503-26. DOI: 10.1007/s10928-008-9099-z. View

Hooker A, Ten Tije A, Carducci M, Weber J, Garrett-Mayer E, Gelderblom H . Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. Clin Pharmacol Ther. 2008; 84(1):111-8. PMC: 3092481. DOI: 10.1038/sj.clpt.6100476. View

Ribbing J, Jonsson E . Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. J Pharmacokinet Pharmacodyn. 2004; 31(2):109-34. DOI: 10.1023/b:jopa.0000034404.86036.72. View

Bergstrand M, Hooker A, Wallin J, Karlsson M . Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011; 13(2):143-51. PMC: 3085712. DOI: 10.1208/s12248-011-9255-z. View

Mould D, Holford N, Schellens J, Beijnen J, Hutson P, Rosing H . Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther. 2002; 71(5):334-48. DOI: 10.1067/mcp.2002.123553. View

Ahn J, Karlsson M, Dunne A, Ludden T . Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn. 2008; 35(4):401-21. DOI: 10.1007/s10928-008-9094-4. View

Upton R, Foster D, Christrup L, Dale O, Moksnes K, Popper L . A physiologically-based recirculatory meta-model for nasal fentanyl in man. J Pharmacokinet Pharmacodyn. 2012; 39(5):561-76. DOI: 10.1007/s10928-012-9268-y. View

Petersson K, Hanze E, Savic R, Karlsson M . Semiparametric distributions with estimated shape parameters. Pharm Res. 2009; 26(9):2174-85. DOI: 10.1007/s11095-009-9931-1. View

Mould D, Upton R . Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol. 2013; 1:e6. PMC: 3606044. DOI: 10.1038/psp.2012.4. View

10.

Yafune A, Ishiguro M . Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. I: A use of bootstrap standard error. Stat Med. 1999; 18(5):581-99. DOI: 10.1002/(sici)1097-0258(19990315)18:5<581::aid-sim47>3.0.co;2-1. View

11.

Nestorov I . Whole-body physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol. 2007; 3(2):235-49. DOI: 10.1517/17425255.3.2.235. View

12.

Gibiansky L, Gibiansky E, Bauer R . Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model. J Pharmacokinet Pharmacodyn. 2011; 39(1):17-35. DOI: 10.1007/s10928-011-9228-y. View

13.

Yano Y, Beal S, Sheiner L . Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001; 28(2):171-92. DOI: 10.1023/a:1011555016423. View

14.

Lacey L, Keene O, PRITCHARD J, Bye A . Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed?. J Biopharm Stat. 1997; 7(1):171-8. DOI: 10.1080/10543409708835177. View

15.

Bergstrand M, Karlsson M . Handling data below the limit of quantification in mixed effect models. AAPS J. 2009; 11(2):371-80. PMC: 2691472. DOI: 10.1208/s12248-009-9112-5. View

16.

Oberg A, Davidian M . Estimating data transformations in nonlinear mixed effects models. Biometrics. 2000; 56(1):65-72. DOI: 10.1111/j.0006-341x.2000.00065.x. View

17.

Beal S . Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2002; 28(5):481-504. DOI: 10.1023/a:1012299115260. View

18.

Nikkelen E, van Meurs W, Ohrn M . Hydraulic analog for simultaneous representation of pharmacokinetics and pharmacodynamics: application to vecuronium. J Clin Monit Comput. 1999; 14(5):329-37. DOI: 10.1023/a:1009996221826. View

19.

Holford N . A size standard for pharmacokinetics. Clin Pharmacokinet. 1996; 30(5):329-32. DOI: 10.2165/00003088-199630050-00001. View

20.

Wang Y . Derivation of various NONMEM estimation methods. J Pharmacokinet Pharmacodyn. 2007; 34(5):575-93. DOI: 10.1007/s10928-007-9060-6. View